Since its formation in 2004, pharmaceutical manufacturer Aesica has more than tripled both sales and employee figures while successfully wooing the industry’s biggest hitters. No spoonful of sugar required, either, as Edward Machin discovers.
As a supplier of active pharmaceutical ingredients, formulations and custom synthesis solutions to the global pharmaceutical and biotechnology industries, Aesica’s product portfolio reads like a roll call of modern medicinal offerings: anti-infectives; cardiovasculars; anaesthetics; haematinics; anti-inflammatories; anti-virals; hormones; and potent drugs, among many others. It was, however, not always the case. “Created in 2004 by…
This content is for subscribers only. Subscribe now for free to read the full article.
Already a subscriber? Login
